SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-26-004877 to Jade Biosciences, Inc. (JBIO)

Jade Biosciences, Inc.
Date: May 13, 2026 · CIK: 0001798749 · Accession: 0000000000-26-004877

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-295665

Date
May 13, 2026
Author
Elizabeth Balta, Esq.
Form
UPLOAD
Company
Jade Biosciences, Inc.

Letter

May 13, 2026 Elizabeth Balta, Esq. Chief Legal Officer and Corporate Secretary Jade Biosciences, Inc. 221 Crescent St., Building 23, Suite 105 Waltham, MA 02453 Re: Jade Biosciences, Inc. Registration Statement on Form S-3 Filed May 07, 2026 File No. 333-295665 Dear Elizabeth Balta Esq.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Matthew T. Bush, Esq.

Show Raw Text
May 13, 2026
Elizabeth Balta, Esq.
Chief Legal Officer and Corporate Secretary
Jade Biosciences, Inc.
221 Crescent St., Building 23, Suite 105
Waltham, MA 02453
Re: Jade Biosciences, Inc.
Registration Statement on Form S-3
Filed May 07, 2026
File No. 333-295665
Dear Elizabeth Balta Esq.:
 This is to advise you that we have not reviewed and will not review your registration
statement.
 Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
 Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Matthew T. Bush, Esq.